BRPI0415121A - material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida - Google Patents
material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólidaInfo
- Publication number
- BRPI0415121A BRPI0415121A BRPI0415121-6A BRPI0415121A BRPI0415121A BR PI0415121 A BRPI0415121 A BR PI0415121A BR PI0415121 A BRPI0415121 A BR PI0415121A BR PI0415121 A BRPI0415121 A BR PI0415121A
- Authority
- BR
- Brazil
- Prior art keywords
- solid dosage
- dosage form
- particulate material
- manufacturing
- fibrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301503 | 2003-10-10 | ||
DKPA200400464 | 2004-03-23 | ||
PCT/DK2004/000668 WO2005034908A2 (en) | 2003-10-10 | 2004-10-01 | A solid dosage form comprising a fibrate and a statin |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0415121A true BRPI0415121A (pt) | 2006-11-28 |
Family
ID=34436500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0415121-6A BRPI0415121A (pt) | 2003-10-10 | 2004-10-01 | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida |
Country Status (10)
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04009385A (es) | 2002-03-26 | 2005-01-25 | Teva Pharma | Microparticulas de drogas. |
WO2006037344A1 (en) * | 2004-10-01 | 2006-04-13 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and atorvastatin |
JPWO2006011495A1 (ja) * | 2004-07-30 | 2008-05-01 | 興和株式会社 | 高コレステロール血症及び/又は高トリグリセリド血症治療剤 |
JP2008509154A (ja) | 2004-08-06 | 2008-03-27 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なスタチン薬剤組成物および関連治療方法 |
WO2006037345A1 (en) * | 2004-10-01 | 2006-04-13 | Lifecycle Pharma A/S | Pharmaceutical composition comprising fenofibrate and simvastatin |
WO2006037348A1 (en) * | 2004-10-01 | 2006-04-13 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and a statin |
WO2006059224A1 (en) * | 2004-12-02 | 2006-06-08 | Warner-Lambert Company Llc | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
EP1707197A1 (en) * | 2005-03-30 | 2006-10-04 | Teva Pharmaceutical Industries Ltd. | Formulations containing fenofibrate and a surfactant mixture |
JP2008534586A (ja) * | 2005-03-30 | 2008-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | フェノフィブレートの改良された製剤 |
EP1861084A1 (en) * | 2005-03-30 | 2007-12-05 | Teva Pharmaceutical Industries Ltd. | Improved formulations of fenofibrate containing menthol or peg/poloxamer |
WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
JP2007008923A (ja) * | 2005-05-31 | 2007-01-18 | Aska Pharmaceutical Co Ltd | フィブラート系薬剤を含有する製剤及びその製造方法 |
BRPI0520821A2 (pt) * | 2005-12-28 | 2009-06-30 | Teva Pharma | formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada |
EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
JP2009542693A (ja) * | 2006-07-06 | 2009-12-03 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物動態が制御された組成物 |
US20090318496A1 (en) | 2006-08-04 | 2009-12-24 | Aska Pharmaceutical Co., Ltd. | Preparation containing fibrate agent and process for producing the same |
US7569612B1 (en) | 2006-08-21 | 2009-08-04 | Mutual Pharmaceutical Company, Inc. | Methods of use of fenofibric acid |
CZ300047B6 (cs) * | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
US7872560B2 (en) * | 2007-03-19 | 2011-01-18 | Abc Taiwan Electronics Corp. | Independent planar transformer |
JP5600058B2 (ja) * | 2007-04-11 | 2014-10-01 | ファーマシューティカル プロダクションズ, インコーポレイテッド | メラトニンタブレットならびに調剤及び使用方法 |
PL2200588T3 (pl) * | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
EP2214635A1 (en) * | 2007-10-19 | 2010-08-11 | Purdue Research Foundation | Solid formulations of crystalline compounds |
GR1006173B (el) * | 2007-12-21 | 2008-11-26 | Ανωνυμος Φαρμακευτικη-Χημικη Βιομηχανια Medichromα.Ε. | Χημικη συνθεση του (3r, 5r) - διυδροξυ - 7 - [2-(4-φθοροφαινυλ) - 5 - σοπροπυλ - 3 - φαινυλ - 4 - φαινυλκαρβαμοϋλο - πυρρολυλο - τριενυδρο - επτανοϊκου ασβεστιου, εφαρμογη φαρμακευτικου σκευασματος και παραγωγικη διαδικασια |
CA2718255C (en) * | 2008-03-11 | 2016-08-23 | Aska Pharmaceutical Co., Ltd. | Solid dispersion and pharmaceutical composition of the same, and production processes thereof |
EA201591353A1 (ru) * | 2008-05-02 | 2016-01-29 | Джилид Сайэнс, Инк. | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента |
WO2009142421A2 (ko) * | 2008-05-17 | 2009-11-26 | 한올제약주식회사 | 약제학적 제제 |
EP2374459A1 (en) * | 2008-05-30 | 2011-10-12 | Psychogenics Inc. | Treatment for neurological and mental disorders |
MX2011006307A (es) * | 2008-12-15 | 2011-10-14 | Banner Pharmacaps Inc | Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua. |
JPWO2010092925A1 (ja) * | 2009-02-12 | 2012-08-16 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
JP2012096998A (ja) * | 2009-02-27 | 2012-05-24 | Kowa Co | 安定なカプセル製剤及びその製造方法 |
CA2780941C (en) * | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
JP2013521249A (ja) | 2010-03-05 | 2013-06-10 | ビーエーエスエフ ソシエタス・ヨーロピア | 融解物で被覆された医薬形態 |
TR201005326A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Çoklu dozaj formları. |
KR101302243B1 (ko) * | 2010-07-28 | 2013-09-02 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
WO2012027222A1 (en) | 2010-08-24 | 2012-03-01 | Rutgers, The State University Of New Jersey | Formulation and manufacture of pharmaceuticals by impregnation onto porous carriers |
AU2012301602B2 (en) * | 2011-09-01 | 2015-09-03 | Vascular Biogenics Ltd. | Formulations and dosage forms of oxidized phospholipids |
US9849184B2 (en) * | 2011-12-14 | 2017-12-26 | Lts Lohmann Therapie-Systeme Ag | Wafer and capsule formulations with enhanced dissolution rates for fenofibrate |
HUE037732T2 (hu) * | 2012-04-18 | 2018-09-28 | Contera Pharma Aps | A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény |
JP2013224285A (ja) * | 2012-06-27 | 2013-10-31 | Kowa Co | 医薬 |
RU2547574C2 (ru) * | 2013-07-09 | 2015-04-10 | Общество с ограниченной ответственностью "Трейдсервис" | Лекарственная форма гиполипидемического действия и способ ее изготовления |
RU2572705C1 (ru) * | 2014-11-25 | 2016-01-20 | Татьяна Георгиевна Неустроева | Композиция для полоскания полости рта |
WO2018011181A1 (en) | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
BR112019002031A2 (pt) * | 2016-08-05 | 2019-05-14 | Taurus Development Company Llc | formulação de calcitonina oral estável em temperatura ambiente |
US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
EP3381479A1 (de) * | 2017-03-29 | 2018-10-03 | ARTOSS GmbH | Trägerzusammensetzung für knochenersatzmaterialien |
US11672781B2 (en) | 2018-05-07 | 2023-06-13 | Prana Biosciences Inc | Metaxalone formulations |
JP2022542004A (ja) | 2019-07-31 | 2022-09-29 | インタス ファーマシューティカルズ リミテッド | HMG-CoAレダクターゼ阻害剤及びフェノフィブラートを含む医薬組成物 |
PE20240141A1 (es) * | 2020-09-29 | 2024-02-01 | Laboratorios Silanes S A De C V | Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares |
CN113143882A (zh) * | 2021-04-30 | 2021-07-23 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
KR102501636B1 (ko) * | 2021-12-07 | 2023-02-21 | 에이스바이오팜 주식회사 | 페노피브린산을 포함하는 경구용 정제 및 이의 제조방법 |
WO2023146320A1 (ko) * | 2022-01-28 | 2023-08-03 | 동광제약 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603143A (en) * | 1983-05-02 | 1986-07-29 | Basf Corporation | Free-flowing, high density, fat soluble vitamin powders with improved stability |
US4613676A (en) * | 1983-11-23 | 1986-09-23 | Ciba-Geigy Corporation | Substituted 5-amino-4-hydroxyvaleryl derivatives |
FR2557459B1 (fr) * | 1984-01-02 | 1986-05-30 | Lhd Lab Hygiene Dietetique | Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice |
GB8413191D0 (en) * | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
US4710228A (en) * | 1985-10-16 | 1987-12-01 | General Mills, Inc. | Edible coating composition and method of preparation |
US4816264A (en) * | 1986-06-06 | 1989-03-28 | Warner-Lambert Company | Sustained release formulations |
FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
US6096337A (en) * | 1996-06-10 | 2000-08-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US6287587B2 (en) * | 1997-07-15 | 2001-09-11 | Takeda Chemical Industries, Ltd. | Process for producing sustained-release preparation by in-water drying |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
DE19840256A1 (de) * | 1998-09-03 | 2000-03-09 | Basf Ag | Verfahren zur Herstellung von beschichteten festen Dosierungsformen |
CA2253769C (en) * | 1998-11-10 | 2000-09-26 | Bernard Charles Sherman | Pharmaceutical compositions comprising fenofibrate |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
KR100331529B1 (ko) * | 1999-06-16 | 2002-04-06 | 민경윤 | 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법 |
EP1175205B1 (en) * | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
US20020058065A1 (en) * | 2000-09-20 | 2002-05-16 | Pol-Henri Guivarc'h | Insoluble drug particle compositions with improved fasted-fed effects |
AU6294501A (en) * | 2000-09-20 | 2002-04-02 | Rtp Pharma Inc | Spray drying process and compositions of fenofibrate |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
JP2002212075A (ja) * | 2001-01-17 | 2002-07-31 | Otsuka Pharmaceut Factory Inc | 脂肪乳剤及び医薬製剤 |
US6534088B2 (en) * | 2001-02-22 | 2003-03-18 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
US20030212102A1 (en) * | 2001-06-12 | 2003-11-13 | Koretke Todd W | Novel solid dispersion compositions |
JP4570357B2 (ja) * | 2001-07-06 | 2010-10-27 | ライフサイクル ファーマ エー/エス | 制御された凝集 |
CA2456732C (en) * | 2001-08-07 | 2012-10-30 | Galephar M/F | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030162827A1 (en) * | 2002-01-30 | 2003-08-28 | Suresh Venkataram | HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition |
US20040005339A1 (en) * | 2002-06-28 | 2004-01-08 | Shojaei Amir H. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
EP1601347A1 (en) * | 2003-02-19 | 2005-12-07 | LifeCycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
JP2006524190A (ja) * | 2003-02-20 | 2006-10-26 | テバ ファーマシューティカル インダストリーズ リミティド | 薬剤のメントール溶液 |
EP1861084A1 (en) * | 2005-03-30 | 2007-12-05 | Teva Pharmaceutical Industries Ltd. | Improved formulations of fenofibrate containing menthol or peg/poloxamer |
JP2008534586A (ja) * | 2005-03-30 | 2008-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | フェノフィブレートの改良された製剤 |
US20070148233A1 (en) * | 2005-12-28 | 2007-06-28 | Lerner E I | Pharmaceutical formulations of fenofibrate having improved bioavailability |
US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
-
2004
- 2004-10-01 BR BRPI0415121-6A patent/BRPI0415121A/pt not_active IP Right Cessation
- 2004-10-01 WO PCT/DK2004/000668 patent/WO2005034908A2/en active Application Filing
- 2004-10-01 JP JP2006529649A patent/JP2007508249A/ja active Pending
- 2004-10-01 EP EP04762888A patent/EP1680086A2/en not_active Withdrawn
- 2004-10-01 RU RU2006115596/15A patent/RU2343905C2/ru not_active IP Right Cessation
- 2004-10-01 KR KR1020067006884A patent/KR20060085682A/ko not_active Application Discontinuation
- 2004-10-01 US US10/513,778 patent/US20060068015A1/en not_active Abandoned
- 2004-10-01 CA CA002541382A patent/CA2541382A1/en not_active Abandoned
- 2004-10-01 MX MXPA06003813A patent/MXPA06003813A/es not_active Application Discontinuation
- 2004-11-15 US US10/988,828 patent/US20060105050A1/en not_active Abandoned
- 2004-11-15 US US10/988,917 patent/US20070009603A1/en not_active Abandoned
-
2009
- 2009-05-12 AU AU2009201881A patent/AU2009201881A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA06003813A (es) | 2006-06-14 |
US20060105050A1 (en) | 2006-05-18 |
US20070009603A1 (en) | 2007-01-11 |
KR20060085682A (ko) | 2006-07-27 |
CA2541382A1 (en) | 2005-04-21 |
AU2004279661A1 (en) | 2005-04-21 |
WO2005034908A3 (en) | 2005-08-11 |
EP1680086A2 (en) | 2006-07-19 |
RU2343905C2 (ru) | 2009-01-20 |
JP2007508249A (ja) | 2007-04-05 |
AU2009201881A1 (en) | 2009-06-04 |
WO2005034908A2 (en) | 2005-04-21 |
US20060068015A1 (en) | 2006-03-30 |
RU2006115596A (ru) | 2007-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0415121A (pt) | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida | |
BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0520669A2 (pt) | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina | |
UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
ATE478840T1 (de) | 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung | |
BRPI0409516A (pt) | composição, uso de uma composição e processo de melhora da penetração de um ativo farmacêutico | |
BRPI0414000B8 (pt) | composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica | |
ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
BRPI0312649A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. | |
BR0100949A (pt) | Inibição da degradação oxidativa de formulaçõesfarmacêuticas | |
ATE485049T1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
ATE275393T1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
BR0318278A (pt) | compostos de éter aminocicloexìlico e usos dos mesmo | |
BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
ATE476997T1 (de) | Zusammensetzung und dosierform mit einer festen oder halbfesten matrix | |
BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
ATE499939T1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
BR9915694A (pt) | Composições compreendendo cefuroxima axetil | |
UY27727A1 (es) | Nueva composicion farmacéutica- | |
BR0313220A (pt) | Pelìcula de revestimento para comprimidos e cápsulas | |
CL2009000980A1 (es) | Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006). | |
EP1584335A3 (en) | Active substance combination comprising a carbinol composition and an opioid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |